Enzymatica's new rights issue completed - will be provided with SEK 60 million
May 11 2016 - 5:14AM
This press release may not be
published or distributed, directly or indirectly, in or into the
United States, Australia, Japan, Canada, Hong Kong, New Zealand,
Singapore or South Africa or any other jurisdiction where such
action is subject to legal restrictions.
The subscription period for
Enzymatica AB (publ)'s ("Enzymatica" or the "Company") rights issue
with preferential rights for the Company's shareholders ended on 6
May 2016 and the final result shows that approximately 56 per cent
of the rights issue was subscribed for through preferential rights
and that applications for subscription without preferential rights
corresponding to approximately 10 per cent of the rights issue have
been made. The remaining 34 per cent have been subscribed for by
underwriters. The Company will be provided with approximately SEK
60 million before costs associated with the rights issue.
- |
We are
very satisfied with the result of the new rights issue and
particularly of the interest to subscribe by shareholders,
management, board of directors and new long-term strategic
investors. We will now have the possibility to run the company
according to our long-term strategy with international expansion,
says Fredrik Lindberg, CEO of Enzymatica. |
The final result of Enzymatica's rights issue
shows that approximately 15.3 million shares, corresponding to
approximately 56 per cent of the offered shares, were subscribed
for through preferential rights. In addition, applications for
subscription of approximately 2.8 million shares, corresponding to
approximately 10 per cent of the offered shares, without
preferential rights have been made.
The remaining part of the rights issue, which
amounts to approximately 9.4 million shares and corresponds to
approximately 34 per cent of the offered shares, have been
subscribed for by underwriters who have undertaken to subscribe for
and pay for any part of the rights issue not subscribed for with or
without preferential rights.
Those who have subscribed for shares without
preferential rights will be allocated shares in accordance with the
principles set out in the prospectus published on 20 April 2016.
Notices will be distributed to those who have subscribed for shares
without preferential rights shortly.
Through the rights issue, Enzymatica will be
provided with approximately SEK 60 million before costs associated
with the rights issue. The Company's share capital will increase
with approximately SEK 1,100,817.48 to approximately SEK
2,935,513.27 and the total number of shares and votes will increase
with 27,520,428 to 73,387,808 shares and votes when the rights
issue has been registered with the Swedish Companies Registration
Office (Sw. Bolagsverket).
The new shares are estimated to be eligible for
trading at NASDAQ First North as of May 25, 2016.
ABG Sundal Collier is financial advisor and
Setterwalls Advokatbyrå is legal advisor to Enzymatica in relation
to the new issue with preemptive rights for existing
shareholders.
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser
Bankaktiebolag.
Important
information
The information in this press release does not contain or
constitute an offer to acquire, subscribe or otherwise trade in
shares, subscription rights or other securities in Enzymatica AB
(publ).
This press release may not be published or
distributed, directly or indirectly in or into the United States,
Australia, Japan, Canada, Hong Kong, New Zeeland, Singapore or
South Africa or any other jurisdiction where such action is wholly
or partially subject to legal restrictions or where such action
would require additional prospectuses, registrations or other
actions in addition to what follows from Swedish law. Nor may the
information in this press release be forwarded, reproduced or
disclosed in such a manner that contravenes such restrictions or
would require such requirements. Failure to comply with this
instruction may result in a violation of applicable securities
laws.
No subscription rights, interim shares or new
shares have been registered, and will not be registered, under the
United States Securities Act of 1933 ("Securities Act") or
securities legislation in any other state or other jurisdiction in
the United States and may not be offered, subscribed, sold or
transferred, directly or indirectly within the United States, other
than pursuant to an exemption from the registration requirements of
the Securities Act and in accordance with securities laws in
relevant state or other jurisdiction in the United States.
This press release may contain forward-looking
statements which reflect Enzymatica AB (publ):s current view on
future events and financial and operational development. Words such
as "intend", "expect", "anticipate", "may", "believe", "plan",
"estimate" and other expressions which imply indications or
predictions of future development or trends, and which are not
based on historical facts, are intended to identify forward-looking
statements. Forward-looking statements inherently involve both
known and unknown risks and uncertainties because they depend on
future events and circumstances. Forward-looking statements do not
guarantee future results or development and the real outcome could
differ materially from the forward-looking statements.
Press release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#2011697
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024